PBAC's latest decision on Raxtozinameran: Deferred (2025). Considered for Prevention of COVID-19 disease caused by SARS-CoV-2 in adults aged ≥18 years at increased risk of severe COVID-19 disease, as booster vaccination (annual or biannual depending on age and risk status).
PBAC outcome
Deferred
Restricted
ICER (AUD/QALY)
Redacted
commercial-in-confidence
Submissions
1
first 2025
Submissions
1
2025 → 2025
Eligible population
Adults aged ≥18 years at increased risk of severe COVID-19 disease (including those aged 18–64 years at standard or high risk, aged 65–74 years at any risk, and aged ≥75 years at any risk), with severe immunocompromise receiving annual or biannual booster doses.
Therapy area
Vaccines
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
Other
Comparator
no (booster) vaccine
Economic model
CUA
ICER note
ICER value not stated in public text; cost-effectiveness analysis was conducted but specific numeric ICER not published in PSD.